Development and validation of a 10-gene signature for predicting recurrence risk in HR+/HER2- early breast cancer undergoing chemo-endocrine therapy
The 10-gene risk score can serve as a tool to predict recurrence risk in HR+/HER2- EBC patients following C-ET, assisting clinicians in developing personalized treatment plans for high-risk patients and ultimately improving patient prognosis.
Authors
- Xun‐Xi Lu (ORCID: https://orcid.org/0000-0002-5118-0377)
- Wenchuan Zhang (ORCID: https://orcid.org/0000-0001-9632-6424)
- Zhang Zhang (ORCID: https://orcid.org/0000-0002-4822-4471)
- Xiaoyan Wu
- Xiaorong Zhong
- Hong Bu (ORCID: https://orcid.org/0000-0001-7472-6443)
Institutions
- Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
Publication Details
- Journal
- The Breast
- Published
- 2025-04-24
- DOI
- https://doi.org/10.1016/j.breast.2025.104484
- Citations
- 4
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 3.75
Funders
- Chengdu Science and Technology Bureau
- Sichuan Province Science and Technology Support Program
- Chengdu Science and Technology Program